google-site-verification: googlec7193c3de77668c9.html

GLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes

[

GLP-1 receptor agonist use does not increase insulin discontinuation with Type 2 diabetes

For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering agents, according to a study published online July 14 in the Annals of Internal Medicine.

Kasia J. Lipska, MD, from the Yale School of Medicine in New Haven, Connecticut, and colleagues compared rates of insulin discontinuation among veterans with T2D receiving basal insulin who initiated treatment with a GLP-1 RA, sodium-glucose cotransporter 2 inhibitor (SGLT2i) or dipeptidyl peptidase-4 inhibitor (DPP-4i) between 2020 and 2022 in a target trial emulation. Data were included for 8,869 matched sets of GLP-1 RA, SGLT2i and DPP-4i initiators.

The researchers found that in the intention-to-treat analysis, 16.7%, 17.9% and 17.1% of GLP-1 RA, SGLT2i and DPP-4i initiators, respectively, discontinued insulin therapy over three years of follow-up (risk ratios, 0.93 [95% confidence interval, 0.86 to 1.01] and 0.98 [95% confidence interval, 0.87 to 1.09] for GLP-1 RA versus SGLT2i and DPP-4i, respectively). In a modified per-protocol analysis, results were not substantively different. With respect to insulin discontinuation, there was no comparative advantage for GLP-1 RAs over SGLT2is or DPP-4is in any subgroup.

“Although GLP-1 RAs remain valuable for their cardiovascular, renal and weight benefits, their initiation alone does not seem to drive basal insulin discontinuation beyond that observed with other glucose-lowering agents,” the authors write.

Publication details

Kasia J. Lipska et al, Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes, Annals of Internal Medicine (2026). DOI: 10.7326/annals-25-05216

Journal information:
Annals of Internal Medicine


Key medical concepts

Diabetes Type 2Glucagon-Like Peptide-1 Receptor Agonists

Clinical categories

Endocrinology

Who’s behind this story?


Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news.

Full profile →


Andrew Zinin

Andrew Zinin

Master’s in physics with research experience. Long-time science news enthusiast. Plays key role in Science X’s editorial success.

Full profile →

Advertisements

© 2026 HealthDay. All rights reserved.

Citation:
GLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes (2026, July 16)
retrieved 17 July 2026
from https://medicalxpress.com/news/2026-07-glp-receptor-agonist-insulin-discontinuation.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Source link

Views: 1

See also  Implantable 'charging station' boosts fight against cancer

Check Also

Early warning signs of potential drug resistance in schistosomiasis parasite revealed

[ Scientists have identified genetic changes in wild populations of the parasitic worm that causes …

What people look at most reflects their brains’ specialization

[ Consistent gaze tendencies towards faces and text in complex scenes. a,b, The consistency of …

Brain circuits may help explain cognitive symptoms in progressive supranuclear palsy

[ Researchers at Japan’s National Institutes for Quantum Science and Technology (QST) have found that …

Leave a Reply

Available for Amazon Prime